The program compared Cleviprex to current intravenous antihypertensive agents: nitroglycerin, sodium nitroprusside or nicardipine. Cleviprex met all primary endpoints in the trial.
“Given the trial successfully met all of its primary endpoints, this marks the completion of our phase III efforts for Cleviprex. The Medicines Company remains committed and on track to expeditiously move forward with an NDA submission before the end of June,” said John Kelley, president and COO of The Medicines Company.
Cleviprex is a first third-generation dihydropyridine calcium channel blocker that acts rapidly and reliably, is vascular and arterial selective, and has an ultra short half-life.